Skip to main content

Table 2 Predictors of persistent anemia after 12 months of ART among 102 HIV-infected adults who were anemic at ART initiation

From: Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania

    Crudea Adjustedb
Variables Total Anemic after 12 months (%) OR (95% CI) P OR (95% CI) P
Gender       
   Female 75 30 (40.0) 1    
   Male 27 9 (33.3) 0.85 (0.33-2.20) 0.744   
Age (years)       
   <30 26 10 (38.5) 1    
   30-39 42 19 (45.2) 1.45 (0.52-4.01) 0.476   
   ≥40 34 10 (29.4) 0.77 (0.25-2.33) 0.641   
AIDSc       
   No 41 16 (39.0) 1    
   Yes 61 23 (37.7) 0.93 (0.41-2.13) 0.862   
Tuberculosisd       
   No 80 31 (38.8) 1    
   Yes 22 8 (36.4) 0.69 (0.24-1.94) 0.477   
BMI (kg/m2)       
   <16 26 9 (34.6) 1    
   16-18.4 35 15 (42.9) 1.62 (0.55-4.78) 0.382   
   ≥18.5 40 14 (35.0) 1.24 (0.42-3.64) 0.702   
MCV (fL)       
   ≥87.5 25 6 (24.0) 1   1  
   82.1-87.4 27 9 (33.3) 1.47 (0.43-5.06) 0.538 1.35 (0.38-4.72) 0.644
   76.0-82.0 25 9 (36.0) 1.75 (0.51-6.00) 0.377 1.42 (0.39-5.13) 0.595
   <76.0 25 15 (60.0) 4.05 (1.17-14.1) 0.028 4.34 (1.22-15.5) 0.023
MCH (pg)       
   ≥28.1 26 7 (26.9) 1    
   26.6-28.0 24 7 (29.2) 1.14 (0.33-3.95) 0.841   
   23.8-26.5 26 10 (38.5) 1.70 (0.52-5.52) 0.380   
   <23.8 26 15 (57.7) 3.20 (0.97-10.5) 0.056   
Initial regimen       
   Stavudine 79 27 (34.2) 1   1  
   Zidovudine 23 12 (52.2) 2.46 (0.93-6.54) 0.071 2.91 (1.03-8.19) 0.043
  1. aAdjusted for baseline hemoglobin. bAdjusted for baseline hemoglobin and the other variables listed in the final model. MCH was excluded because of collinearity with MCV. cWorld Health Organization clinical stage 4. dOn tuberculosis treatment at ART initiation or started within the observation period of 12 months.
  2. OR, odds ratio; CI, confidence interval; BMI, body mass index; MCV, mean cell volume; MCH, mean corpuscular hemoglobin.